ArticleAdvanced healthcare materials2022
Mucosomes: Intrinsically Mucoadhesive Glycosylated Mucin Nanoparticles as Multi-Drug Delivery Platform.
Article in Advanced healthcare materials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- Reversible, Chemically Triggered Water Retention in Disulfide Cross-Linked Synthetic Conserved Anterior Mucus Proteins (SCAMPs).Macromolecules · 2026Article
- DoE-Optimized Chitosan-Coated pH-Sensitive Liposomes for Targeted Nose-to-Brain Delivery of Temozolomide.AAPS PharmSciTech · 2026Article
- Current status of intranasal and inhaled COVID-19 vaccines.NPJ vaccines · 2026Review
- Mucoadhesive nanofibers for ocular drug delivery: mechanisms, design strategies, and applications.Drug delivery and translational research · 2026Review
- Mucopenetrative Lipid-Polymer nanoparticles show Potent Anti-Inflammatory activity in a human Lung-on-Chip model.International journal of pharmaceutics · 2026Article
- Current Status and Future Prospects on Nanodelivery Systems Targeting the Small Intestine for Absorption of Bioactive Substances.Foods (Basel, Switzerland) · 2025Review
- The hidden piece in inflammatory bowel diseases: The significance of intestinal mucus in mediating the bacteria-cells crosstalk.Materials today. Bio · 2025Review
- Multi-Functional Polydopamine-Mucin Hollow Particles Provide Tunable Shell Permeability, ROS Scavenging, Tissue Adhesion, and Lubricity for Biomedical Applications.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Mucosomes as next-generation drug carriers for treating mucus-resident bacterial infections and biofilms.Scientific reports · 2025Article
- Nanomedicine Innovations for Lung Cancer Diagnosis and Therapy.ACS applied materials & interfaces · 2025Review
- Pulmonary mucinous adenocarcinoma: An overview of pathophysiology and advancements in treatment.Heliyon · 2024Review
- Fabrication and Characterization of Mucin Nanoparticles for Drug Delivery Applications.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Mucoadhesive Mesoporous Silica Particles as Versatile Carriers for Doxorubicin Delivery in Cancer Therapy.International journal of molecular sciences · 2023Article
- A Fast and Reliable Method Based on QCM-D Instrumentation for the Screening of Nanoparticle/Blood Protein Interactions.Biosensors · 2023Article
- Crosslinked Chitosan Nanoparticles with Muco-Adhesive Potential for Intranasal Delivery Applications.International journal of molecular sciences · 2023Article
- Increasing Bioavailability of Trans-Ferulic Acid by Encapsulation in Functionalized Mesoporous Silica.Pharmaceutics · 2023Article
- Recombinant mucin biotechnology and engineering.Advanced drug delivery reviews · 2023Review
- Mucosomes: Intrinsically Mucoadhesive Glycosylated Mucin Nanoparticles as Multi-Drug Delivery Platform.Advanced healthcare materials · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucus is a complex barrier for pharmacological treatments and overcoming it is one of the major challenges faced during transmucosal drug delivery. To tackle this issue, a novel class of glycosylated nanoparticles, named "mucosomes," which are based on the most important protein constituting mucus, the mucin, is introduced. Mucosomes are designed to improve drug absorption and residence time on the mucosal tissues. Mucosomes are produced (150-300 nm), functionalized with glycans, and loaded with the desired drug in a single one-pot synthetic process and, with this method, a wide range of small and macro molecules can be loaded with different physicochemical properties. Various in vitro models are used to test the mucoadhesive properties of mucosomes. The presence of functional glycans is indicated by the interaction with lectins. Mucosomes are proven to be storable at 4 °C after lyophilization, and administration through a nasal spray does not modify the morphology of the mucosomes. In vitro and in vivo tests indicate mucosomes do not induce adverse effects under the investigated conditions. This study proposes mucosomes as a ground-breaking nanosystem that can be applied in several pathological contexts, especially in mucus-related disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.